Due to the current understanding of malignant metabolism and a lack of curative MM treatment, these promising results indicate that targeting MYC-dependent glutamine-metabolism in MM may provide a supplementary strategy for future therapies. This evidence concerns the gene MYC and Miyoshi myopathy.